PracticeVideosBlogFlashcardsEspañol

Free exam prep

BCOP Board Certified Oncology Pharmacist

Practice QuestionsStudy Guide

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer

Key Takeaways

  • Neoadjuvant chemoimmunotherapy with nivolumab plus platinum-doublet chemotherapy (CheckMate 816) or perioperative pembrolizumab (KEYNOTE-671) substantially improves pathologic complete response (pCR) and event-free survival (EFS) in resectable Stage IB (>=4 cm) to IIIA NSCLC.
  • Adjuvant osimertinib (ADAURA) for 3 years is the standard of care for resected Stage IB–IIIA EGFR-mutated (Ex19del or L858R) NSCLC following surgery and optional adjuvant chemotherapy, demonstrating an extraordinary overall survival benefit (5-year OS 88% vs 78%; HR 0.49).
  • Consolidation durvalumab for up to 12 months (PACIFIC trial) is the benchmark standard of care for patients with unresectable Stage III NSCLC whose disease has not progressed following definitive concurrent platinum-based chemoradiotherapy (cCRT), providing durable 5-year OS benefit (42.9% vs 33.4%).
  • Limited-stage SCLC (LS-SCLC) is treated with curative-intent concurrent cisplatin plus etoposide with accelerated hyperfractionated thoracic radiotherapy (45 Gy BID or 60–70 Gy QD) followed by prophylactic cranial irradiation (PCI) for responders and consolidation durvalumab (ADRIATIC).
  • Extensive-stage SCLC (ES-SCLC) frontline standard of care is platinum doublet plus anti-PD-L1 chemoimmunotherapy (atezolizumab via IMpower133 or durvalumab via CASPIAN); relapsed disease is managed with lurbinectedin, topotecan, or the DLL3-directed bispecific T-cell engager tarlatamab.
Last updated: August 2026

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer

Thoracic malignancies represent the leading cause of cancer-related mortality globally. Lung carcinomas are pathologically categorized into Non-Small Cell Lung Cancer (NSCLC) (~85% of diagnoses, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and Small Cell Lung Cancer (SCLC) (~15% of diagnoses, characterized by aggressive neuroendocrine biology and rapid hematogenous dissemination).

Over the past decade, multimodal paradigms for early-stage and locally advanced thoracic cancers have shifted dramatically from empiric surgical resection and cytotoxic chemoradiation toward biomarker-directed perioperative chemoimmunotherapy, adjuvant kinase inhibition, and post-chemoradiation checkpoint consolidation. Clinical oncology pharmacists must master the pharmacology, trial evidence, dosing logistics, and toxicity interception strategies across these curative-intent and advanced disease settings.

1. Staging, Functional Assessment, and Resectability in Early-Stage NSCLC

Accurate staging according to the AJCC TNM 8th/9th Edition and rigorous pretreatment functional evaluation dictate the boundary between resectable disease, locally advanced unresectable disease, and metastatic carcinoma.

+-----------------------------------------------------------------------------+
|                  EARLY & LOCALLY ADVANCED NSCLC STAGING SPECTRUM            |
|                                                                             |
|   STAGE I: Primary tumor <=4 cm (T1a-T2a), Node-Negative (N0)               |
|   - Stage IA: Tumor <=3 cm, N0 -> Curative Surgical Resection / SBRT         |
|   - Stage IB: Tumor >3 cm to <=4 cm, N0 -> Resection +/- Adjuvant Therapy    |
|                                                                             |
|   STAGE II: Primary tumor 4-7 cm (T2b-T3) OR Ipsilateral Peribronchial/     |
|             Hilar Node Involvement (N1)                                     |
|   - Stage IIA: T2b (>4 to <=5 cm) N0                                        |
|   - Stage IIB: T1a-T2b N1 OR T3 (>5 to <=7 cm) N0                           |
|   ---> Standard: Resection + Perioperative Chemoimmunotherapy / Adjuvant    |
|                                                                             |
|   STAGE III: Locally Advanced / Mediastinal Nodal Disease                   |
|   - Stage IIIA: Ipsilateral Mediastinal / Subcarinal Nodes (N2) (Select Res.)|
|   - Stage IIIB: Contralateral Mediastinal / Supraclavicular Nodes (N3)      |
|   - Stage IIIC: Multiple T3-T4 Tumors with N3 Nodal Spread (Unresectable)   |
|   ---> Standard IIIB/IIIC: Definitive Concurrent Chemoradiotherapy + PACIFIC|
+-----------------------------------------------------------------------------+

Clinical Staging & Diagnostic Modalities

  • Invasive Mediastinal Staging: Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) or mediastinoscopy is mandatory for clinical Stage >=II or centrally located tumors to confirm nodal status before surgical resection.
  • Brain MRI & Integrated PET/CT: Dedicated contrast-enhanced brain MRI and whole-body 18F-FDG PET/CT are required for all clinical Stage II–III patients to rule out occult intracranial or distant visceral metastases.
  • Cardiopulmonary Clearance: Baseline Spirometry (FEV1), Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), and cardiopulmonary exercise testing (VO2 max) determine surgical tolerance for lobectomy vs. pneumonectomy.

2. Perioperative Therapeutics in Resectable NSCLC (Stages IB–IIIA)

Historically, postoperative adjuvant cisplatin-based chemotherapy provided an absolute 5-year overall survival (OS) advantage of only 5.4% across resected Stage II–IIIA patients (LACE meta-analysis). Modern clinical practice integrates neoadjuvant chemoimmunotherapy, adjuvant immune checkpoint inhibitors (ICIs), and targeted adjuvant kinase inhibitors.

+-----------------------------------------------------------------------------+
|              PERIOPERATIVE ALGORITHMS FOR RESECTABLE NSCLC (STAGE IB-IIIA)  |
|                                                                             |
|                     [RESECTABLE NSCLC CONFIRMED]                            |
|                                  |                                          |
|         +------------------------+------------------------+                 |
|         |                                                 |                 |
|         v                                                 v                 |
|  [EGFR / ALK DRIVER POSITIVE]                     [DRIVER NEGATIVE / WT]    |
|         |                                                 |                 |
|         v                                                 v                 |
|  [Upfront Surgical Resection]                    [Select Neoadjuvant vs     |
|         |                                         Upfront Surgery Approach] |
|         v                                                 |                 |
|  [Adjuvant Cisplatin Doublet]                             |                 |
|         |                                                 |                 |
|         +----------------+                                |                 |
|         |                |                                |                 |
|         v                v                                v                 |
|  [EGFR Ex19del/L858R] [ALK Fusion]               +----------------+         |
|  Osimertinib 80 mg PO  Alectinib 600 mg BID      | NEOADJUVANT    |         |
|  Daily x 3 Years       PO x 2 Years              | Nivolumab +    |         |
|  (ADAURA Trial)        (ALINA Trial)             | Chemo x 3 c    |         |
|                                                  | (CheckMate 816)|         |
|                                                  +--------+-------+         |
|                                                           |                 |
|                                                           v                 |
|                                                  [Surgical Resection]       |
|                                                           |                 |
|                                                           v                 |
|                                                  [PERIOPERATIVE ALT]        |
|                                                  KEYNOTE-671: Pembrolizumab |
|                                                  x 4c pre-op -> Surgery ->  |
|                                                  Pembrolizumab x 13c post-op|
+-----------------------------------------------------------------------------+

Neoadjuvant Chemoimmunotherapy

  • CheckMate 816 Trial (Nivolumab + Platinum Doublet): Evaluated 3 cycles of neoadjuvant nivolumab (360 mg IV Q3W) plus platinum-doublet chemotherapy versus chemotherapy alone in resectable Stage IB (>=4 cm) to IIIA NSCLC. The addition of nivolumab increased the Pathologic Complete Response (pCR) rate from 2.2% to 24.0% (p < 0.001) and significantly prolonged Event-Free Survival (EFS: HR 0.63, p = 0.005) without compromising surgical feasibility or increasing perioperative mortality.
  • KEYNOTE-671 Trial (Perioperative Pembrolizumab): Evaluated neoadjuvant pembrolizumab (200 mg Q3W) plus cisplatin-based chemotherapy for 4 cycles prior to surgery, followed by adjuvant single-agent pembrolizumab (200 mg Q3W) for up to 13 cycles (approx. 1 year). Demonstrates statistically significant improvements in both EFS (HR 0.58) and Overall Survival (OS: HR 0.72, p = 0.005).
  • AEGEAN Trial (Perioperative Durvalumab): Neoadjuvant durvalumab + platinum doublet x 4 cycles followed by adjuvant durvalumab x 12 cycles showed superior pCR (17.2% vs 4.3%) and EFS (HR 0.68).

Adjuvant Targeted Kinase Inhibition

  • ADAURA Trial (Adjuvant Osimertinib): Phase 3 trial in completely resected Stage IB–IIIA EGFR-mutated (Exon 19 deletion or Exon 21 L858R) NSCLC. Following complete surgical recovery and standard adjuvant platinum-doublet chemotherapy (or no chemotherapy based on clinician discretion), patients received osimertinib 80 mg orally once daily for up to 3 years versus placebo.
    • Results: Dramatic disease-free survival advantage (DFS HR 0.20 in Stage II–IIIA; HR 0.27 in overall population) and landmark Overall Survival benefit (5-year OS: 88% vs. 78%; HR 0.49, p < 0.001). Central nervous system recurrence was reduced by 82% (CNS DFS HR 0.18).
  • ALINA Trial (Adjuvant Alectinib): Phase 3 trial evaluating adjuvant alectinib 600 mg orally twice daily for 2 years versus platinum-based chemotherapy in resected Stage IB (>=4 cm) to IIIA ALK-rearranged NSCLC. Alectinib demonstrated an unprecedented reduction in disease recurrence or death (DFS HR 0.24, p < 0.001) and marked intracranial disease control.

Adjuvant Immune Checkpoint Inhibition (Driver-Negative Resected NSCLC)

  • IMpower010 Trial (Atezolizumab): Following complete resection and adjuvant platinum chemotherapy, atezolizumab 1200 mg IV Q3W for 1 year (16 cycles) demonstrated significant DFS improvement in Stage II–IIIA patients whose tumors express PD-L1 >=1% (SP263 assay; DFS HR 0.66), with the greatest benefit in PD-L1 >=50% (DFS HR 0.43).
  • KEYNOTE-091 / PEARLS Trial (Pembrolizumab): Adjuvant pembrolizumab 200 mg IV Q3W for 1 year (18 doses) showed significant DFS improvement across resected Stage IB (>=4 cm) to IIIA NSCLC regardless of PD-L1 expression.

Standard Adjuvant Platinum-Based Chemotherapy Regimens

Histology SubtypePreferred Platinum DoubletRegimen Dosing & ScheduleSupportive Care & Clinical Pearls
Non-SquamousCisplatin + PemetrexedCisplatin 75 mg/m2 IV Day 1 + Pemetrexed 500 mg/m2 IV Day 1 Q21D x 4 cyclesSuperior tolerability and OS in non-squamous histology. Mandatory supplementation: Folic acid 400–1000 mcg PO daily, Vitamin B12 1000 mcg IM Q9–12 weeks, Dexamethasone 4 mg PO BID (Days -1, 0, +1). CrCl must be >=45 mL/min.
SquamousCisplatin + GemcitabineCisplatin 75–80 mg/m2 IV Day 1 + Gemcitabine 1000–1250 mg/m2 Days 1, 8 Q21D x 4 cyclesPemetrexed is ineffective in squamous histology due to elevated thymidylate synthase expression. Monitor for gemcitabine thrombocytopenia and hemolytic uremic syndrome (rare).
Any HistologyCisplatin + VinorelbineCisplatin 75–80 mg/m2 IV Day 1 + Vinorelbine 25–30 mg/m2 Days 1, 8 Q21D x 4 cyclesClassic historical standard (IALT/ANITA). High rates of severe nausea, severe neutropenia, constipation, and peripheral neuropathy. Vinorelbine is a potent vesicant.
Any HistologyCisplatin + DocetaxelCisplatin 75 mg/m2 IV Day 1 + Docetaxel 75 mg/m2 IV Day 1 Q21D x 4 cyclesPremedicate with oral dexamethasone 8 mg BID for 3 days starting the day prior to docetaxel to prevent hypersensitivity reactions and severe capillary fluid retention.

3. Unresectable Stage III Locally Advanced NSCLC (The PACIFIC Protocol)

Approximately 30% of NSCLC patients present with locally advanced, unresectable Stage III disease (bulky N2/N3 mediastinal lymphadenopathy, invasion of vital mediastinal structures). The curative-intent benchmark is Definitive Concurrent Chemoradiotherapy (cCRT) followed by Consolidation Durvalumab.

+-----------------------------------------------------------------------------+
|                 THE CURATIVE-INTENT PACIFIC TREATMENT PARADIGM              |
|                                                                             |
|   [DEFINITIVE CONCURRENT CHEMORADIOTHERAPY (cCRT)]                          |
|   - Radiation: 60 to 66 Gy in 30 to 33 daily fractions (1.8-2.0 Gy/fx)      |
|   - Concurrent Chemotherapy Doublet (4 cycles total):                       |
|     * Cisplatin 50 mg/m2 D1, 8, 29, 36 + Etoposide 50 mg/m2 D1-5, 29-33     |
|     * Carboplatin AUC 2 + Paclitaxel 45-50 mg/m2 IV weekly during RT        |
|     * Cisplatin 75 mg/m2 D1 + Pemetrexed 500 mg/m2 D1 Q21D x 3c (Non-squam) |
|                                   |                                         |
|                                   v                                         |
|   [RESTAGING CT SCAN (1-42 DAYS POST-RADIATION)]                            |
|   - Confirm absence of progressive disease and resolution of acute toxicities|
|                                   |                                         |
|                                   v                                         |
|   [CONSOLIDATION IMMUNOTHERAPY: DURVALUMAB (PACIFIC)]                       |
|   - Durvalumab 10 mg/kg IV Q2W OR 1500 mg IV Q4W for up to 12 MONTHS       |
|   - Landmark Efficacy: 5-Year Overall Survival 42.9% vs 33.4% (HR 0.72)     |
|   - Median PFS: 16.9 months vs 5.6 months (HR 0.55)                         |
+-----------------------------------------------------------------------------+

Critical Clinical Pharmacist Considerations in Stage III NSCLC

  1. Concurrent vs. Sequential CRT: Concurrent chemoradiotherapy is clinically superior to sequential therapy, providing a 4.5% absolute 5-year OS benefit, despite higher rates of acute Grade 3/4 esophagitis.
  2. Radiation Pneumonitis vs. Immune-Mediated Pneumonitis:
    • Distinguishing radiation-induced pneumonitis (typically confined to the high-dose radiation field within 1–6 months of RT) from checkpoint inhibitor pneumonitis (diffuse, bilateral, migratory ground-glass opacities outside radiation portals).
    • For Grade 2 immune pneumonitis: Withhold durvalumab and initiate oral prednisone 1–2 mg/kg/day with slow taper over >=4–6 weeks. For Grade 3/4 pneumonitis: Permanently discontinue durvalumab, admit patient, and administer IV methylprednisolone 2–4 mg/kg/day plus empiric pulmonary infection coverage.
  3. Durvalumab Initiation Window: In the PACIFIC trial, initiating durvalumab within 1 to 42 days after completing cCRT was permitted. Subgroup analyses demonstrated enhanced efficacy when durvalumab was started within <14 days of RT completion, provided radiation-induced pneumonitis/esophagitis had subsided to Grade <=1.

4. Small Cell Lung Cancer (SCLC): Pathophysiology and Staging

Small Cell Lung Cancer is a high-grade neuroendocrine carcinoma defined by distinct molecular and clinical characteristics:

  • Pathognomonic Genomic Alterations: Near-universal biallelic inactivation of both TP53 (>90%) and RB1 (>95%), alongside frequent amplification of MYC family oncogenes.
  • Neuroendocrine Biomarkers: Strongly positive for synaptophysin, chromogranin A, CD56 (NCAM), and INSM1 on immunohistochemistry (IHC). Ki-67 proliferation index is typically >80–90%.
  • Paraneoplastic Syndromes: High propensity for ectopic hormone secretion:
    • SIADH (Syndrome of Inappropriate Antidiuretic Hormone): Ectopic ADH secretion causing euvolemic hyponatremia. Managed with fluid restriction, hypertonic 3% NaCl if symptomatic/severe, or oral vasopressin V2 receptor antagonists (tolvaptan).
    • Cushing Syndrome: Ectopic ACTH secretion causing severe hypokalemia, metabolic alkalosis, and hyperglycemia. Managed with ketoconazole or osilodrostat.
    • Lambert-Eaton Myasthenic Syndrome (LEMS): Autoantibodies against presynaptic P/Q-type voltage-gated calcium channels causing proximal muscle weakness that improves with repetitive exertion. Managed with 3,4-diaminopyridine (amifampridine).
+-----------------------------------------------------------------------------+
|                        SCLC STAGING DICHOTOMY (VALG)                        |
|                                                                             |
|   LIMITED-STAGE SCLC (LS-SCLC) [~30% of Patients]                           |
|   - Confined to one hemithorax, mediastinum, and ipsilateral supraclavicular|
|     lymph nodes that can be safely encompassed in a single radiation port.  |
|   - Primary Goal: CURATIVE INTENT (Median OS 25-30 months; 5-yr OS 25-30%)  |
|   - Modality: Concurrent ChemoRT (EP + Accelerated TRT) + PCI + Durvalumab  |
|                                                                             |
|   EXTENSIVE-STAGE SCLC (ES-SCLC) [~70% of Patients]                         |
|   - Disease extending beyond limited-stage boundaries: contralateral lung   |
|     nodules, distant hematogenous metastases (liver, bone, brain, adrenal), |
|     or malignant pleural/pericardial effusions.                             |
|   - Primary Goal: PALLIATION & OS PROLONGATION (Median OS 12-13 months)     |
|   - Modality: Frontline Chemoimmunotherapy (EP + Atezolizumab / Durvalumab) |
+-----------------------------------------------------------------------------+

5. Limited-Stage SCLC (LS-SCLC) Multimodal Management

+-----------------------------------------------------------------------------+
|                     LS-SCLC MULTIMODAL THERAPY PROTOCOL                     |
|                                                                             |
|   [CONCURRENT CHEMORADIOTHERAPY (cCRT)]                                     |
|   - Chemotherapy (Cycle 1 begins on Day 1 of Radiation):                    |
|     * Cisplatin 60 mg/m2 IV Day 1 + Etoposide 120 mg/m2 IV Days 1, 2, 3     |
|     * (Or Cisplatin 75-80 mg/m2 D1 + Etoposide 100 mg/m2 D1-3) Q21D x 4 c   |
|   - Accelerated Hyperfractionated Thoracic Radiotherapy (Turrisi Regimen):  |
|     * 45 Gy total delivered as 1.5 Gy BID (twice daily) over 3 weeks (30 fx)|
|     * Alternative: Once-daily 60 to 70 Gy in 30-35 fractions                |
|                                   |                                         |
|                                   v                                         |
|   [RESTAGING POST-cCRT (CHEST/ABDOMEN CT + BRAIN MRI)]                      |
|                                   |                                         |
|         +-------------------------+-------------------------+               |
|         |                                                   |               |
|         v                                                   v               |
|  [COMPLETE / GOOD PARTIAL RESPONSE]                [PROGRESSIVE DISEASE]    |
|         |                                                   |               |
|         v                                                   v               |
|  [PROPHYLACTIC CRANIAL IRRADIATION (PCI)]          [Second-Line Therapy]    |
|  - 25 Gy in 10 daily fractions                                              |
|  - Reduces brain metastases from ~60% to ~30%                               |
|  - Confers ~5.4% absolute 3-year OS benefit                                 |
|         |                                                                   |
|         v                                                                   |
|  [CONSOLIDATION DURVALUMAB (ADRIATIC Trial)]                                |
|  - Statistically significant OS and PFS prolongation post-cCRT              |
+-----------------------------------------------------------------------------+

Clinical Nuances in LS-SCLC Chemoradiation

  • Early vs. Late RT: Initiating thoracic radiotherapy early (concurrently with Cycle 1 or Cycle 2 of cisplatin/etoposide) produces superior survival compared to delaying RT to later cycles.
  • Cisplatin vs. Carboplatin in LS-SCLC: While cisplatin plus etoposide (EP) remains the historical reference standard in curative LS-SCLC, carboplatin (AUC 5–6 Day 1) plus etoposide is an accepted alternative for patients with preexisting renal impairment (CrCl <60 mL/min), baseline neuropathy, or severe hearing loss, without compromising long-term survival.
  • Growth Factor Restriction: Granulocyte colony-stimulating factors (G-CSF: filgrastim, pegfilgrastim) should be avoided during active concurrent thoracic radiation due to documented risks of severe inflammatory lung injury, pulmonary hemorrhage, and fatal radiation pneumonitis. G-CSF should only be used if severe neutropenic complications occur, or reserved for post-radiation cycles.

6. Extensive-Stage SCLC (ES-SCLC) Systemic Therapeutics

For over three decades, platinum-etoposide chemotherapy alone was the standard for ES-SCLC, with a median OS of 9–10 months. The addition of anti-PD-L1 immune checkpoint inhibitors established a new frontline standard of care.

+-----------------------------------------------------------------------------+
|                 ES-SCLC FRONTLINE CHEMOIMMUNOTHERAPY PARADIGMS              |
|                                                                             |
|   1. IMpower133 PROTOCOL:                                                   |
|      - Induction (4 Cycles Q21D):                                           |
|        * Carboplatin AUC 5 IV Day 1                                         |
|        * Etoposide 100 mg/m2 IV Days 1, 2, 3                                |
|        * Atezolizumab 1200 mg IV Day 1                                      |
|      - Maintenance:                                                         |
|        * Atezolizumab 1200 mg IV Q3W (or 1680 mg Q4W) until progression     |
|      - Efficacy: mOS 12.3 vs 10.3 months (HR 0.70, p = 0.007); 2-yr OS 22%  |
|                                                                             |
|   2. CASPIAN PROTOCOL:                                                      |
|      - Induction (4 Cycles Q21D):                                           |
|        * Cisplatin 75-80 mg/m2 D1 (OR Carboplatin AUC 5-6 D1)               |
|        * Etoposide 100 mg/m2 IV Days 1, 2, 3                                |
|        * Durvalumab 1500 mg IV Day 1                                        |
|      - Maintenance:                                                         |
|        * Durvalumab 1500 mg IV Q4W until disease progression                |
|      - Efficacy: mOS 12.9 vs 10.5 months (HR 0.73, p = 0.001); 3-yr OS 18%  |
+-----------------------------------------------------------------------------+

Brain Metastases and Prophylactic Cranial Irradiation in ES-SCLC

In ES-SCLC, the routine use of PCI has been largely replaced by active surveillance with contrast-enhanced brain MRI every 3 months and stereotactic radiosurgery (SRS) or whole-brain radiation therapy (WBRT) upon radiographic intracranial progression. The Japanese Phase 3 trial (Takahashi et al.) demonstrated that in ES-SCLC patients undergoing routine MRI surveillance, PCI did not prolong overall survival (mOS 10.1 vs 15.1 months, HR 1.27) and caused neurocognitive decline.

7. Relapsed and Refractory SCLC Management

Treatment selection upon disease progression depends primarily on the chemotherapy-free interval (CTFI):

+-----------------------------------------------------------------------------+
|                     RELAPSED SCLC TREATMENT SELECTION                       |
|                                                                             |
|   [PLATINUM-SENSITIVE RELAPSE (CTFI >= 6 MONTHS)]                           |
|   - Rechallenge with original frontline Platinum + Etoposide                |
|   - Expected response rate: 40-50%                                          |
|                                                                             |
|   [PLATINUM-RESISTANT / INTERMEDIATE (CTFI < 3-6 MONTHS)]                   |
|   - Prior Chemoimmunotherapy Progression -> Targeted Second-Line Options:   |
|                                                                             |
|     1. LURBINECTEDIN (3.2 mg/m2 IV Q21D)                                    |
|        * Synthetic tetrahydroisoquinoline alkaloid analog                   |
|        * Covalently binds DNA minor groove, inhibits active transcription,  |
|          and depletes tumor-associated macrophages (TAMs)                   |
|        * Overall Response Rate: ~35% (45% in sensitive, 22% in resistant)   |
|        * Key Toxicities: Grade 3/4 Neutropenia (46%), Leukopenia, Transaminitis|
|        * Recommend primary G-CSF prophylaxis and strict antiemetics         |
|                                                                             |
|     2. TARLATAMAB (DLL3 x CD3 Bispecific T-Cell Engager - BiTE)             |
|        * Targets Delta-Like Ligand 3 (DLL3) expressed on >85% of SCLC       |
|        * Directs cytotoxic CD3+ T-cells to lyse neuroendocrine SCLC cells  |
|        * DeLLphi-301 Trial: 10 mg IV Q2W; ORR 40%, median DoR not reached   |
|        * Signature Toxicity: Cytokine Release Syndrome (CRS in 50-60%; step-|
|          up dosing and hospitalization monitoring required) & ICANS         |
|                                                                             |
|     3. TOPOTECAN (1.5 mg/m2 IV Days 1-5 Q21D OR 2.3 mg/m2 PO Days 1-5 Q21D)|
|        * Topoisomerase I inhibitor; historical comparator                   |
|        * Severe, dose-limiting myelosuppression (Grade 4 neutropenia >70%)  |
+-----------------------------------------------------------------------------+

Master Summary Table: Thoracic Malignancy Clinical Practice Milestones

Clinical SettingPrimary Landmark Trial(s)Benchmark RegimenCritical Pharmacist Evaluation Points
Resectable NSCLC (Stage IB-IIIA)CheckMate 816<br>KEYNOTE-671Neoadjuvant Nivolumab (3c) + Platinum Doublet OR Perioperative PembrolizumabScreen for baseline autoimmune disorders; verify staging. pCR rate ~24% with nivolumab combo.
Resected EGFR+ NSCLCADAURAAdjuvant Osimertinib 80 mg PO daily x 3 yearsVerify Ex19del or L858R. Monitor baseline/periodic ECG (QTc) and echocardiogram (LVEF). 5-yr OS HR 0.49.
Resected ALK+ NSCLCALINAAdjuvant Alectinib 600 mg PO BID x 2 yearsTake with food. Monitor CPK, bilirubin, and heart rate (bradycardia). DFS HR 0.24.
Unresectable Stage III NSCLCPACIFICDefinitive cCRT -> Consolidation Durvalumab 1500 mg Q4W x 1 yearInitiate within 1–42 days post-cCRT. Screen for radiation pneumonitis vs. immune-related pneumonitis.
Limited-Stage SCLCTurrisi / Intergroup<br>ADRIATICCisplatin + Etoposide + Concurrent BID RT (45 Gy) -> PCI -> DurvalumabAvoid G-CSF during concurrent radiation. Premedicate for cisplatin nephrotoxicity with aggressive hydration.
Extensive-Stage SCLCIMpower133<br>CASPIANCarboplatin/Cisplatin + Etoposide + Atezolizumab or Durvalumab x 4c -> ICI maintOmit mandatory PCI in favor of regular brain MRI surveillance. Manage etoposide hypotension / extravasation.
Relapsed SCLCDeLLphi-301Lurbinectedin 3.2 mg/m2 Q21D OR Tarlatamab 10 mg Q2WPrimary G-CSF prophylaxis for lurbinectedin; inpatient step-up dosing and CRS/tocilizumab protocols for tarlatamab.
Test Your Knowledge

A 59-year-old female with completely resected Stage IIA (pT2bN0M0) non-squamous non-small cell lung cancer completes 4 cycles of adjuvant cisplatin plus pemetrexed. Molecular NGS analysis confirms the presence of an EGFR Exon 19 deletion (E746_A750del) and wild-type ALK/ROS1. Based on the Phase 3 ADAURA trial, what is the most appropriate evidence-based adjuvant management recommendation?

A
B
C
D
Test Your Knowledge

A 63-year-old male with unresectable Stage IIIB (cT3N2M0) squamous cell carcinoma of the lung successfully completes definitive concurrent chemoradiotherapy (cisplatin 50 mg/m2 on Days 1, 8, 29, 36 plus etoposide 50 mg/m2 on Days 1–5 and 29–33 with 60 Gy thoracic radiation). Restaging chest CT scan at Day 21 post-radiotherapy shows a partial radiographic response with no evidence of disease progression, and acute radiation esophagitis has fully resolved to Grade 0. What is the standard-of-care next step in management according to the PACIFIC trial?

A
B
C
D
Test Your Knowledge

A 66-year-old patient with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC) and asymptomatic bone metastases presents to the multidisciplinary thoracic clinic. The patient has an ECOG performance status of 1 and normal baseline organ function. Which of the following systemic regimens represents the guideline-preferred, Category 1 first-line treatment standard?

A
B
C
D
Test Your Knowledge

A 60-year-old male with extensive-stage small cell lung cancer experienced rapid disease progression 7 weeks after completing 4 cycles of frontline carboplatin, etoposide, and durvalumab (chemotherapy-free interval < 90 days, defining platinum-refractory disease). He has an ECOG performance status of 1, absolute neutrophil count of 2,400/mcL, and total bilirubin 0.8 mg/dL. Which of the following second-line antineoplastic regimens is FDA-approved and evidence-based for this clinical scenario, and what is its primary mechanism of action?

A
B
C
D
Up Next

9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative)

Continue learning